

Dr. Mesa serves as the executive director of the Mays Cancer Center, one of only four National Cancer Institute-designated Cancer Centers in Texas. Dr. Mesa is internationally renowned expert on myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that often lead to leukemia. He has been the principal investigator or co-principal investigator of more than 100 clinical trials and co-led the research teams leading to the FDA's approval of 4 drugs including ruxolitinib, fedratinib, ropegylated interferon, and pacritinib. Dr. Mesa earned his Bachelor of Science degrees in nuclear engineering and physiology, with minors in radiation biophysics and bioengineering, from the University of Illinois at Urbana-Champaign. He received his medical degree, completed his residency in internal medicine and fulfilled his fellowship in hematology/medical oncology from the Mayo Graduate School at the Mayo Clinic College of Medicine in Rochester, Minnesota. He is a fellow of the American College of Physicians and is certified by the American Board of Internal Medicine in internal medicine and medical oncology. Dr. Mesa has been elected to the boards of the American Association of Cancer Institutes and is an officer of the board of the Leukemia and Lymphoma Society.